Business Combinations and Asset Purchases (Narrative) (Details) (USD $)
|
12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 30, 2012
years
|
Jan. 01, 2012
|
Jan. 02, 2011
|
Jan. 03, 2010
|
Oct. 25, 2011
2021 Notes [Member]
|
Dec. 30, 2012
2021 Notes [Member]
|
Jan. 01, 2012
November 2011 Caliper Life Sciences [Member]
|
Jan. 01, 2012
Minimum [Member]
|
Jan. 01, 2012
Maximum [Member]
|
Nov. 30, 2012
Human Health [Member]
November 2012 Haoyuan Biotech Co. [Member]
|
Jun. 30, 2011
Human Health [Member]
June 2011 Dexela Limited [Member]
|
May 31, 2011
Human Health [Member]
May 2011 Geospiza, Inc [Member]
|
Mar. 31, 2011
Human Health [Member]
March 2011 ID Biological Systems, Inc [Member]
|
Feb. 28, 2011
Human Health [Member]
February 2011 Chemagen Biopolymer-Technologie AG [Member]
|
Jan. 01, 2012
Human Health [Member]
November 2011 Caliper Life Sciences [Member]
|
Nov. 30, 2011
Human Health [Member]
November 2011 Caliper Life Sciences [Member]
|
Dec. 30, 2012
Human Health [Member]
Core Technology [Member]
November 2012 Haoyuan Biotech Co. [Member]
|
Jan. 01, 2012
Human Health [Member]
Core Technology [Member]
November 2011 Caliper Life Sciences [Member]
|
Dec. 30, 2012
Human Health [Member]
Trade Names [Member]
November 2012 Haoyuan Biotech Co. [Member]
|
Jan. 01, 2012
Human Health [Member]
Trade Names [Member]
November 2011 Caliper Life Sciences [Member]
|
Jan. 01, 2012
Human Health [Member]
Licenses [Member]
November 2011 Caliper Life Sciences [Member]
|
Jan. 01, 2012
Human Health [Member]
Customer Relationships [Member]
November 2011 Caliper Life Sciences [Member]
|
May 31, 2011
Environmental Health [Member]
May 2011 Labtronics, Inc [Member]
|
Apr. 30, 2011
Environmental Health [Member]
April 2011 CambridgeSoft Corporation [Member]
|
Mar. 31, 2011
Environmental Health [Member]
March 2011 ArtusLabs, Inc [Member]
|
|
Business Acquisition [Line Items] | |||||||||||||||||||||||||
Business Acquisition, Purchase Price Allocation Adjustment, Current Assets | $ 20,800,000 | ||||||||||||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | 26,100,000 | 13,200,000 | 34,600,000 | 11,400,000 | |||||||||||||||||||||
Business Acquisition, Cost of Acquired Entity, Cash Paid | 38,000,000 | 24,800,000 | 13,250,000 | 7,664,000 | 33,873,000 | 646,317,000 | 11,389,000 | 227,373,000 | 15,232,000 | ||||||||||||||||
Unsecured senior notes, face value | 500,000,000 | 500,000,000 | |||||||||||||||||||||||
Proceeds from the issuance of debt instrument | 496,900,000 | ||||||||||||||||||||||||
Debt instrument maturity date | Nov. 25, 2021 | ||||||||||||||||||||||||
Unsecured senior notes, interest rate percent | 5.00% | ||||||||||||||||||||||||
Working capital and other adjustments | (2,729,000) | 1,251,000 | 729,000 | 0 | 762,000 | 29,000 | (4,156,000) | 0 | |||||||||||||||||
Gain on step acquisition | 0 | 0 | (25,586,000) | ||||||||||||||||||||||
Aggregate revenue from immaterial acquisitions | 32,400,000 | ||||||||||||||||||||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 3,017,000 | 20,298,000 | 1,731,000 | 4,251,000 | |||||||||||||||||||||
Business Combination, Contingent Consideration Arrangements, Description | P3Y | ||||||||||||||||||||||||
Additional contingent consideration | 61,300,000 | 30,000,000 | 12,200,000 | 3,300,000 | 20,300,000 | 15,000,000 | |||||||||||||||||||
Contingent consideration | 1,900,000 | 4,600,000 | 0 | 326,000 | 7,723,000 | 0 | 0 | 7,475,000 | |||||||||||||||||
Weighted average amortization period (in years) | 7 years | 11 years | 8 years | 5 years | 8 years | 7 years | 6 years | 7 years | |||||||||||||||||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | 29,300,000 | ||||||||||||||||||||||||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | (3,000,000) | ||||||||||||||||||||||||
Deferred revenue acquisition liability | 0 | 0 | 380,000 | 0 | 0 | 6,554,000 | 315,000 | 9,504,000 | 297,000 | ||||||||||||||||
Total transaction costs | 1,200,000 | 10,700,000 | 2,600,000 | ||||||||||||||||||||||
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | 1 | ||||||||||||||||||||||||
Business Acquisition, Purchase Price Allocation Adjustment, Goodwill Amount | 600,000 | ||||||||||||||||||||||||
Business Acquisition, Purchase Price Allocation Adjustment, Other Noncurrent Liabilities | 22,800,000 | ||||||||||||||||||||||||
Business Acquisition, Purchase Price Allocation Adjustment, Current Liabilities, Accrued Liabilities | $ (1,400,000) |